Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. (NVCT) Market Cap

Nuvectis Pharma, Inc. has a market capitalization of $222.1M.

Financials based on reported quarter end 2025-12-31

Price: $8.38

โ–ฒ 0.06 (0.66%)

Market Cap: 222.13M

NASDAQ ยท time unavailable

CEO: Ron Bentsur

Sector: Healthcare

Industry: Biotechnology

IPO Date: 2022-02-04

Website: https://www.nuvectis.com

Nuvectis Pharma, Inc. (NVCT) - Company Information

Market Cap: 222.13M ยท Sector: Healthcare

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.

Analyst Sentiment

83%
Strong Buy

Based on 2 ratings

Analyst 1Y Forecast: $10.00

Average target (based on 1 sources)

Consensus Price Target

Low

$10

Median

$10

High

$10

Average

$10

Potential Upside: 19.3%

Price & Moving Averages

Loading chart...

Fundamentals Overview

Loading fundamentals overview...

๐Ÿ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"NVCT reported minimal revenue of $0 and a net loss of $7.314M for the recent quarter. The company has faced substantial challenges, as evidenced by negative operating cash flow of $4.494M. With total assets of $31.709M, offset by total liabilities of $13.296M, NVCT maintains a healthy equity position of $18.413M and a net cash surplus, indicating strong financial backing. Despite these strengths, shareholder sentiment remains negative, reflected by a significant 18.96% decrease in share price over the past year. However, there was a notable 32.50% rebound in the past six months. The outlook remains uncertain with no dividend payments and ongoing operating losses, positioning NVCT as an entity that has yet to achieve revenue generation. The analyst consensus price target indicates stable expectations but lacks optimism given the current financial trajectory."

Revenue Growth

Neutral

Company is pre-revenue.

Profitability

Neutral

Negatively impacted with a net loss of $7.314M.

Cash Flow Quality

Neutral

Negative operating cash flow of $4.494M.

Leverage & Balance Sheet

Positive

Strong equity position with net cash surplus.

Shareholder Returns

Neutral

Price declined by 18.96% over the past year.

Analyst Sentiment & Valuation

Caution

Stable price targets suggest cautious optimism.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Loading financial data and tables...
๐Ÿ“

SEC Filings (NVCT)

ยฉ 2026 Stock Market Info โ€” Nuvectis Pharma, Inc. (NVCT) Financial Profile